Ipsen Deal Revamp Increases Independence for Inspiration

A new license, development and commercialization agreement between Inspiration Biopharmaceuticals Inc., of Cambridge, Mass., and Paris-based Ispen SA will restructure the existing partnership between the firms and provide additional funding to Inspiration for development of hemophilia drugs IB1001 and OBI-1.

"Ipsen's been a good partner throughout these negotiations. We both have the same goal in mind, to help patients with hemophilia," Inspiration's chief commercial officer, Dan Regan, told BioWorld Today.